Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Manual for Tracking down the Mysterious Cascades in China01.01.1 - 2The Significance of Prenuptial Arrangements in Separation Procedures30.06.2023
- 3Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle06.06.2024
- 4The Most Paramount Crossroads in Olympic History07.07.2023
- 5Manual for extravagance SUVs for seniors05.06.2024
- Building a Maintainable Closet: Individual Excursions in Moral Style
- The Craft of Computerized Detox: Individual Trials
- Instructions to Keep up with Your Traded Teeth for Life span
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- 5 things for parents to know about changes to kids vaccine schedule
- 75% of US adults may meet criteria for obesity under new definition, study finds
- Instructions to Pick the Right Tires for Your Slam 1500.
- Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
